> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 5 Observations in Dr. Reddy’s FDA-483
- URL: https://www.fdaweb.com/5-observations-in-dr-reddys-fda-483/
- Published: 2020-02-06T12:00:00.000Z
- Updated: 2026-09-14T16:02:04.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146037

FDA has released the FDA-483 issued following a 1/20-1/28 inspection at the Dr. Reddy’s API manufacturing facility in Srikakulam District, Andhra Pradesh, India. The five observations on the [form](https://www.fda.gov/media/134938/download?ref=fdaweb.com) were: 

- failing to adequately perform process validation for manufactured products at the facility;
- investigations are inadequate in that they do not evaluate all potential root causes;
- failing to adequately establish and validate cleaning processes for equipment;
- failing to conduct trend analysis of manufactured APIs; and
- the quality unit lacks oversight of quality documents.